Biotechnology company Vect-Horus has signed a global licence agreement with Novo Nordisk for the development of targeted therapeutics.
The agreement grants Novo Nordisk an exclusive worldwide licence to utilise Vect-Horus’s VECTrans platform technology for delivering cargo aimed at specific targets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Vect-Horus co-founder and CEO Alexandre Tokay stated: “This agreement is another important step in our strategy to establish commercial partnerships and to secure significant short-term cash to implement our technology and development programmes.
“We look forward to collaborating with Novo Nordisk to unlock the potential of our technology platform and develop more efficient treatments.”
Vect-Horus will be eligible for an upfront payment and has the option to earn up to $327m in additional developmental, regulatory and commercial milestones across three programmes, along with receiving €40m in subsidies and equity.
The company will also receive tiered royalties on sales of the products.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNovo Nordisk Global Research Technologies senior vice-president Brian Vandahl stated: “We are thrilled to work with Vect-Horus by leveraging their platform to discover optimal delivery for specified targets.
“It is an exemplary opportunity for us to utilise external collaboration to further fuel our own innovation processes, with a common goal of improving health outcomes.”
Vect-Horus is focused on the design and development of vectors that enable targeting and delivery of imaging or therapeutic agents to organs, including the brain, and to tumours.
